PMID- 19621668
OWN - NLM
STAT- MEDLINE
DCOM- 20090917
LR  - 20131121
IS  - 0172-6390 (Print)
IS  - 0172-6390 (Linking)
VI  - 56
IP  - 91-92
DP  - 2009 May-Jun
TI  - Little necessity of acid inhibition against proton pump inhibitor rebound effects 
      and prior helicobacter pylori eradication therapy in gastric ulcer patients: a 
      randomized prospective study.
PG  - 624-8
AB  - BACKGROUND/AIMS: Helicobacter pylori (H. pylori) eradication therapy increases 
      acid secretion and promotes the development of gastroesophageal reflux disease 
      (GERD) and reflux esophagitis (RE). Rebound acid hypersecretion develops after 
      the use of proton pump inhibitors (PPI). We examined the clinical necessity of 
      acid inhibitors to prevent GERD or RE caused by PPI rebound phenomenon and prior 
      H. pylori eradication therapy. METHODOLOGY: We enrolled 39 patients who underwent 
      successful H. pylori eradication therapy prior to endoscopic mucosal resection of 
      gastric cancer. After 8-week rabeprazole treatment for iatrogenic ulcer, they 
      were randomly divided into two groups (who took nizatidine (group N) and 
      sofalcone (group S)), and took each for 16 weeks, we compared RE/GERD symptoms 
      with the baseline by endoscopy and QUEST score. RESULTS: All patients had corpus 
      atrophy in which there was no difference between the two groups. Only 1 patient 
      in group S (5.9%) developed symptomatic GERD, and 1 patient in group N (4.5%) 
      developed RE. CONCLUSIONS: In severe atrophic gastritis patients, there is little 
      clinical necessity of acid inhibitors to prevent GERD/RE caused by PPI rebound 
      and prior H. pylori eradication therapy.
FAU - Wada, Yoshihiro
AU  - Wada Y
AD  - Department of Medicine and Molecular Science, Graduate School of Biomedical 
      Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Ito, Masanori
AU  - Ito M
FAU - Takata, Shunsuke
AU  - Takata S
FAU - Kitamura, Shosuke
AU  - Kitamura S
FAU - Takamura, Akemi
AU  - Takamura A
FAU - Tatsugami, Masana
AU  - Tatsugami M
FAU - Imagawa, Shinobu
AU  - Imagawa S
FAU - Matsumoto, Yoshiaki
AU  - Matsumoto Y
FAU - Tanaka, Shinji
AU  - Tanaka S
FAU - Yoshihara, Masaharu
AU  - Yoshihara M
FAU - Chayama, Kazuaki
AU  - Chayama K
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Greece
TA  - Hepatogastroenterology
JT  - Hepato-gastroenterology
JID - 8007849
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Chalcones)
RN  - 0 (Proton Pump Inhibitors)
RN  - 2B668TJX8E (sofalcone)
RN  - 32828355LL (Rabeprazole)
RN  - P41PML4GHR (Nizatidine)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Chalcones/*therapeutic use
MH  - Cohort Studies
MH  - Esophagitis, Peptic/etiology/pathology/*prevention & control
MH  - Gastroesophageal Reflux/etiology/pathology/*prevention & control
MH  - Helicobacter Infections/therapy
MH  - Helicobacter pylori
MH  - Humans
MH  - Middle Aged
MH  - Nizatidine/*therapeutic use
MH  - Proton Pump Inhibitors/*adverse effects
MH  - Rabeprazole
MH  - Stomach Neoplasms/complications/pathology/surgery
MH  - Stomach Ulcer/drug therapy/etiology/pathology
EDAT- 2009/07/23 09:00
MHDA- 2009/09/18 06:00
CRDT- 2009/07/23 09:00
PHST- 2009/07/23 09:00 [entrez]
PHST- 2009/07/23 09:00 [pubmed]
PHST- 2009/09/18 06:00 [medline]
PST - ppublish
SO  - Hepatogastroenterology. 2009 May-Jun;56(91-92):624-8.